Posting of 2022 Annual Report and Notice of AGM

RNS Number : 2245K

C4X Discovery Holdings PLC

19 December 2022

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Posting of 2022 Annual Report and Notice of AGM

19 December 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it has today published and posted to shareholders the Annual Report and Accounts for the year ended 31 July 2022 and Notice of the Annual General Meeting ("AGM") which will be held at Panmure Gordon, 40 Gracechurch Street, EC3V 0BT , on 24 January 2023 at 11.00 a.m. (GMT).

The Annual Report and Accounts and Notice of AGM are also available to view on, and download from, the Company's website at www.c4xdiscovery.com

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have three commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For further information see www.c4xdiscovery.com

 

END

 

 

NOATLBFTMTIBBLT